Amplia Financial Statements From 2010 to 2024
| INNMF Stock | USD 0.06 0.01 14.49% |
Check Amplia Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amplia Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Amplia financial statements analysis is a perfect complement when working with Amplia Therapeutics Valuation or Volatility modules.
Amplia |
Amplia Therapeutics Limited Company Profit Margin Analysis
Amplia Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Amplia Therapeutics Profit Margin | (1.75) % |
Most of Amplia Therapeutics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amplia Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Amplia Therapeutics Limited has a Profit Margin of -1.7502%. This is 84.39% lower than that of the Healthcare sector and 92.4% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 37.81% higher than that of the company.
Amplia Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amplia Therapeutics's current stock value. Our valuation model uses many indicators to compare Amplia Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amplia Therapeutics competition to find correlations between indicators driving Amplia Therapeutics's intrinsic value. More Info.Amplia Therapeutics Limited is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amplia Therapeutics' earnings, one of the primary drivers of an investment's value.About Amplia Therapeutics Financial Statements
Amplia Therapeutics stakeholders use historical fundamental indicators, such as Amplia Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Amplia Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amplia Therapeutics' assets and liabilities are reflected in the revenues and expenses on Amplia Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amplia Therapeutics Limited. Please read more on our technical analysis and fundamental analysis pages.
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase inhibitors for oncology and chronic fibrosis in Australia. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Innate Immunotherapeuti is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Amplia Pink Sheet
Amplia Therapeutics financial ratios help investors to determine whether Amplia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amplia with respect to the benefits of owning Amplia Therapeutics security.